Increased Prevalence of Antibodies to Hepatitis E Virus in Patients with Neurocysticercosis

被引:0
作者
Abanto, Jesus [1 ,2 ]
Boluarte, Arantxa N. Sanchez [3 ,4 ,9 ]
Castillo, Yesenia [1 ]
Perez, Erika [5 ]
Saavedra, Herbert [5 ]
Gonzales, Isidro [5 ]
Bustos, Javier A. [1 ,5 ]
Abravanel, Florence [6 ]
Izopet, Jacques [6 ]
Madden, Richie G. [7 ,8 ]
Garcia, Hector H. [1 ,5 ]
Dalton, Harry R. [7 ,8 ]
机构
[1] Univ Peruana Cayetano Heredia, Ctr Salud Global, Lima, Peru
[2] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA
[3] Univ Peruana Cayetano Heredia, Fac Med, Lima, Peru
[4] Univ Washington, Dept Global Hlth, Seattle, WA USA
[5] Inst Nacl Ciencias Neurol, Ctr Basico Invest Examenes Auxiliares Parasitosis, Lima, Peru
[6] CHU Purpan, Lab Virol, Toulouse, France
[7] Univ Adelaide, Dept Gastroenterol & Hepatol, Royal Adelaide Hosp, Adelaide, Australia
[8] HEV Int Direct Act Grp HEViDrAG, Adelaide, Australia
[9] Univ Peruana Cayetano Heredia, Sch Med, Ave Honorio Delgado 430, Lima 31, Peru
关键词
PRAZIQUANTEL; ALBENDAZOLE; EFFICACY;
D O I
10.4269/ajtmh.23-0856
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
We explored the association between serological status for hepatitis E and neurocysticercosis (NCC) in neurologic patients attending a national neurological referral center in Lima, Peru, between the years 2008 and 2012. Anti-hepatitis E antibodies were evaluated in patients with and without NCC, and a control group of rural general population. Anti-hepatitis E IgG was found in 23.8% of patients with NCC, compared with 14.3% in subjects without NCC from a general rural population (P = 0.023) and 14.4% in subjects with neurological complaints without NCC (P = 0.027). Seropositive patients had a median age of 44 years compared with 30 years in seronegative patients (P<0.001). No significant differences in sex, region of residence, or liver enzyme values were found. Seropositivity to hepatitis E was frequent in this Peruvian population and higher in patients with NCC, suggesting shared common routes of infection.
引用
收藏
页码:1210 / 1213
页数:4
相关论文
共 50 条
  • [41] Serologic Response to Hepatitis B Vaccination in HIV-Infected Patients with Isolated Positivity for Antibodies to Hepatitis B Core Antigen
    Chakvetadze, Catherine
    Bani-Sadr, Firouze
    Le Pendeven, Catherine
    Lescure, Francois-Xavier
    Fontaine, Camille
    Galperine, Tatiana
    Slama, Laurence
    Bonnard, Philippe
    Mariot, Philippe
    Soussan, Patrick
    Pialoux, Gilles
    CLINICAL INFECTIOUS DISEASES, 2010, 50 (08) : 1184 - 1186
  • [42] Biologics modulate antinuclear antibodies, immunoglobulin E, and eosinophil counts in psoriasis patients
    Sugiura, Riichiro
    Terui, Hitoshi
    Shimada-Omori, Ryoko
    Yamazaki, Emi
    Tsuchiyama, Kenichiro
    Takahashi, Toshiya
    Aiba, Setsuya
    Yamasaki, Kenshi
    JOURNAL OF DERMATOLOGY, 2021, 48 (11) : 1739 - 1744
  • [43] Hepatitis C virus infection in maintenance hemodialysis patients: recommendations for diagnostics and treatment
    Dzekova-Vidimliski, Pavlina
    Sikole, Aleksandar
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2016, 39 (12) : 590 - 595
  • [44] Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis
    Sadler, Matthew D.
    Coffin, Carla S.
    Lee, Samuel S.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) : 1363 - 1369
  • [45] Significance of interferon-β for the treatment of hepatitis C virus infection in hemodialyzed patients
    Zeniya, Mikio
    Yokoyama, Keitaro
    Imamura, Noritsugu
    Murai, Seizo
    Ishikawa, Tomohisa
    Hokari, Atsushi
    Koike, Kazuhiko
    Takahashi, Hiroki
    Sadaoka, Syunichi
    HEPATOLOGY RESEARCH, 2010, 40 (09) : 862 - 869
  • [46] Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
    Elbedewy, Tamer A.
    Elsebaey, Mohamed A.
    Elshweikh, Samah A.
    Elashry, Heba
    Abd-Elsalam, Sherief
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 269 - 274
  • [47] Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection
    Liu, C-H
    Sun, Y.
    Liu, C-J
    Sheng, W-H
    Hsieh, S-M
    Lo, Y-C
    Liu, W-C
    Su, T-H
    Yang, H-C
    Hong, C-M
    Tseng, T-C
    Chen, P-J
    Chen, D-S
    Hung, C-C
    Kao, J-H
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (12) : 1690 - 1698
  • [48] Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis
    Jachs, Mathias
    Binter, Teresa
    Schmidbauer, Caroline
    Hartl, Lukas
    Strasser, Michael
    Laferl, Hermann
    Hametner-Schreil, Stephanie
    Lindorfer, Alexander
    Dax, Kristina
    Stauber, Rudolf E.
    Kessler, Harald H.
    Bernhofer, Sebastian
    Maieron, Andreas
    Loacker, Lorin
    Bota, Simona
    Santonja, Isabel
    Munda, Petra
    Mandorfer, Mattias
    Peck-Radosavljevic, Markus
    Holzmann, Heidemarie
    Gschwantler, Michael
    Zoller, Heinz
    Ferenci, Peter
    Reiberger, Thomas
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2021, 9 (10) : 1119 - 1127
  • [49] Safety of ribavirin in adolescent thalassemic patients with chronic hepatitis C virus infection
    Uslu, Nuray
    Baysoy, Gokhan
    Demir, Hulya
    Temizel, Inci Nur Saltik
    Yuce, Aysel
    JOURNAL OF CLINICAL VIROLOGY, 2010, 48 (01) : 66 - 68
  • [50] Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations
    Freed, Daniel C.
    Towne, Victoria M.
    Casimiro, Danilo R.
    Zhao, Qinjian
    Fu, Tong-Ming
    VACCINE, 2011, 29 (50) : 9385 - 9390